Aims and scope
Multiple Sclerosis and Demyelinating Disorders publishes high-quality, original, basic, and clinical research in the field of multiple sclerosis, neuromyelitis optica and all other demyelinating diseases of the central nervous system.
Main areas of interest include: biochemistry, epidemiology, genetics, health services research, molecular biology, neuroimaging, neuroimmunology, neurology, neuropathology, neuropsychology, neurorehabilitation, pharmacology, physiology, political science, protein chemistry, psychiatry, public policy, sociology, and therapeutics.
The Journal also focuses on areas of research underrepresented in the existing literature, such as the economics and sustainability of multiple sclerosis clinical care, the role of advanced nursing on clinical care of demyelinating disorders, and the impact of stakeholder’s associations on the management of multiple sclerosis.
All articles published by Multiple Sclerosis and Demyelinating Disorders are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Multiple Sclerosis and Demyelinating Disorders you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Multiple Sclerosis and Demyelinating Disorders therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Multiple Sclerosis and Demyelinating Disorders are included in:
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Multiple Sclerosis and Demyelinating Disorders will be available in their databases when appropriate.
Multiple Sclerosis and Demyelinating Disorders operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Multiple Sclerosis and Demyelinating Disorders should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Multiple Sclerosis and Demyelinating Disorders
Articles in Multiple Sclerosis and Demyelinating Disorders should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Mult Scler Demyelinating Disord [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mult Scler Demyelinating Disord 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Multiple Sclerosis and Demyelinating Disorders
Multiple Sclerosis and Demyelinating Disorders's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Multiple Sclerosis and Demyelinating Disorders offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Multiple Sclerosis and Demyelinating Disorders gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Multiple Sclerosis and Demyelinating Disorders are included in article alerts and regular email updates. Some may be highlighted on Multiple Sclerosis and Demyelinating Disorders’s pages and on the BioMed Central homepage.
In addition, articles published in Multiple Sclerosis and Demyelinating Disorders may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Multiple Sclerosis and Demyelinating Disorders. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Multiple Sclerosis and Demyelinating Disorders you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
2016 Journal Metrics
68 days from submission to first decision
26 days from acceptance to publication
735.0 Usage Factor
Social Media Impact